Matches in Ubergraph for { <https://frink.apps.renci.org/.well-known/genid/B51ba8e9581718d5629958e8b51346f32> ?p ?o ?g. }
Showing items 1 to 5 of
5
with 100 items per page.
- B51ba8e9581718d5629958e8b51346f32 NCIT_P378 "NCI" @default.
- B51ba8e9581718d5629958e8b51346f32 type Axiom @default.
- B51ba8e9581718d5629958e8b51346f32 annotatedProperty IAO_0000115 @default.
- B51ba8e9581718d5629958e8b51346f32 annotatedSource NCIT_C165621 @default.
- B51ba8e9581718d5629958e8b51346f32 annotatedTarget "A self-adjuvanted chimeric recombinant protein vaccine, based on the self-adjuvanting KISIMA immunization platform, composed of three components: the 42 residue fragment Z12, a cell penetrating peptide (CPP) derived from the ZEBRA protein transduction domain, a toll-like receptor (TLR) peptide agonist as an adjuvant and a chimeric cargo, a multiple antigenic domain (MAD; MultiE), that contains an as of yet not disclosed amount of major histocompatibility class (MHC)-restricted peptides derived from as of yet undisclosed tumor-associated antigens (TAAs) that are specific for colorectal cancer (CRC) patients, with potential immunomodulating and antineoplastic activities. Upon administration of ATP128, the Z12 moiety targets, binds to and penetrates antigen-presenting cells (APCs), specifically dendritic cells (DCs) and promotes the loading of the epitopes into the DCs and transports antigenic cargoes into both endosomal and cytosolic compartments. Upon processing and antigen presentation by MHC II and I, the immune system is stimulated and activates specific CD4+ and CD8+ T-cells, respectively, against the multi-epitopes specific for the CRC cells, thereby killing the CRC cells." @default.